NCT02834884 2026-04-17
SPECTA
European Organisation for Research and Treatment of Cancer - EORTC
Recruiting
Clinical Trials
15 trialsNCT06756607 2026-04-01
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
Eastern Cooperative Oncology Group
Phase NA Recruiting
NCT05470010 2026-03-27
SEAMLESS
Canadian Cancer Trials Group
Phase NA Recruiting
NCT06391242 2026-03-27
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06630273 2026-03-27
(CAN-IMPACT-IO
Canadian Cancer Trials Group
Not yet recruiting
NCT07390435 2026-03-27
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
Canadian Cancer Trials Group
Not yet recruiting
NCT00082745 2026-03-19
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Children's Oncology Group
Active not recruiting
NCT07427355 2026-02-23
ASANDE
Alliance For Medical Research in Africa
Active not recruiting
NCT05455606 2026-01-22
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
SWOG Cancer Research Network
Phase NA Active not recruiting
NCT00772200 2025-09-18
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Children's Oncology Group
Active not recruiting
NCT01255748 2025-09-09
Registry Study for Radiation Therapy Outcomes
Proton Collaborative Group
Recruiting
NCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT01806129 2025-06-13
EROS
Eastern Cooperative Oncology Group
Phase NA Active not recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting